219 related articles for article (PubMed ID: 35606815)
1. The future of cancer immunotherapy for brain tumors: a collaborative workshop.
Brown CE; Bucktrout S; Butterfield LH; Futer O; Galanis E; Hormigo A; Lim M; Okada H; Prins R; Marr SS; Tanner K
J Transl Med; 2022 May; 20(1):236. PubMed ID: 35606815
[TBL] [Abstract][Full Text] [Related]
2. Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors.
Fogli LK; Aurigemma R; Sommers CL; Singh A; Bourcier K; Ernstoff MS;
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266886
[TBL] [Abstract][Full Text] [Related]
3. Engineering challenges for brain tumor immunotherapy.
Lyon JG; Mokarram N; Saxena T; Carroll SL; Bellamkonda RV
Adv Drug Deliv Rev; 2017 May; 114():19-32. PubMed ID: 28625831
[TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of malignant brain tumors.
Mitchell DA; Fecci PE; Sampson JH
Immunol Rev; 2008 Apr; 222():70-100. PubMed ID: 18363995
[TBL] [Abstract][Full Text] [Related]
6. Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.
Tomaszewski W; Sanchez-Perez L; Gajewski TF; Sampson JH
Clin Cancer Res; 2019 Jul; 25(14):4202-4210. PubMed ID: 30804019
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for brain tumors: understanding early successes and limitations.
Lieberman NAP; Vitanza NA; Crane CA
Expert Rev Neurother; 2018 Mar; 18(3):251-259. PubMed ID: 29322843
[TBL] [Abstract][Full Text] [Related]
8. Developing immunotherapeutic strategies to target brain tumors.
Lieberman NA; Moyes KW; Crane CA
Expert Rev Anticancer Ther; 2016 Jul; 16(7):775-88. PubMed ID: 27253692
[TBL] [Abstract][Full Text] [Related]
9. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
Plant-Fox AS; O'Halloran K; Goldman S
Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development.
Garcia-Fabiani MB; Ventosa M; Comba A; Candolfi M; Nicola Candia AJ; Alghamri MS; Kadiyala P; Carney S; Faisal SM; Schwendeman A; Moon JJ; Scheetz L; Lahann J; Mauser A; Lowenstein PR; Castro MG
Expert Opin Investig Drugs; 2020 Jul; 29(7):659-684. PubMed ID: 32400216
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
12. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies.
Casey DL; Cheung NV
Cancer Immunol Res; 2020 Feb; 8(2):161-166. PubMed ID: 32015013
[TBL] [Abstract][Full Text] [Related]
14. [Brain tumor immunotherapy: Illusion or hope?].
Migliorini D; Dutoit V; Walker PR; Dietrich PY
Bull Cancer; 2017 May; 104(5):476-484. PubMed ID: 28318492
[TBL] [Abstract][Full Text] [Related]
15. Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance.
Owyong M; Hosseini-Nassab N; Efe G; Honkala A; van den Bijgaart RJE; Plaks V; Smith BR
Drug Resist Updat; 2017 Nov; 33-35():23-35. PubMed ID: 29145972
[TBL] [Abstract][Full Text] [Related]
16. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.
Lee Y; Bigner DD
Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097
[TBL] [Abstract][Full Text] [Related]
17. The current state of immunotherapy for primary and secondary brain tumors: similarities and differences.
Nejo T; Mende A; Okada H
Jpn J Clin Oncol; 2020 Oct; 50(11):1231-1245. PubMed ID: 32984905
[TBL] [Abstract][Full Text] [Related]
18. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
19. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
20. Emerging Immunotherapies in the Treatment of Brain Metastases.
Nieblas-Bedolla E; Nayyar N; Singh M; Sullivan RJ; Brastianos PK
Oncologist; 2021 Mar; 26(3):231-241. PubMed ID: 33103803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
